Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2009

AUTHORS

A. Karim Kadar , Christopher G. Wood

ABSTRACT

Renal cell carcinoma (RCC) remains a significant global health problem. Despite inroads in early detection, ̃50 %of patients either present with or develop metastatic disease during the natural history of their illness. There remains no consistent curative therapy for metastatic RCC. For patients with locally advanced disease, surgery remains the mainstay of curative therapy, but a significant number of patients still experience relapse, the risk of which is directly related to the presence of high-risk features at diagnosis. The search for effective adjuvant therapy to decrease the risk of relapse following surgery remains elusive. Therapeutic benefit in the setting of metastatic disease has not translated to success in the adjuvant therapy setting. Numerous clinical trials have examined the role of radiation therapy, immunotherapy, chemotherapy, vaccine therapy, and antiangiogenic therapies in the adjuvant setting. To date, none of these trials have demonstrated a significant benefit. Thus, the standard of care remains surveillance following surgical resection of locally advanced disease. Currently, clinical trials with the new targeted therapies developed for RCC are ongoing in the adjuvant setting. We anxiously await the results of these trials to determine whether they can significantly impact recurrence free and overall survival in the locally advanced setting following curative surgical resection. More... »

PAGES

473-495

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-59745-332-5_25

DOI

http://dx.doi.org/10.1007/978-1-59745-332-5_25

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049745809


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wake Forest University School of Medicine, Winston-Salem, NC", 
          "id": "http://www.grid.ac/institutes/grid.241167.7", 
          "name": [
            "Wake Forest University School of Medicine, Winston-Salem, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kadar", 
        "givenName": "A. Karim", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, MD Anderson Cancer Center, University of Texas, 77030, TX, Houston", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, MD Anderson Cancer Center, University of Texas, 77030, TX, Houston"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009", 
    "datePublishedReg": "2009-01-01", 
    "description": "Renal cell carcinoma (RCC) remains a significant global health problem. Despite inroads in early detection, \u030350 %of patients either present with or develop metastatic disease during the natural history of their illness. There remains no consistent curative therapy for metastatic RCC. For patients with locally advanced disease, surgery remains the mainstay of curative therapy, but a significant number of patients still experience relapse, the risk of which is directly related to the presence of high-risk features at diagnosis. The search for effective adjuvant therapy to decrease the risk of relapse following surgery remains elusive. Therapeutic benefit in the setting of metastatic disease has not translated to success in the adjuvant therapy setting. Numerous clinical trials have examined the role of radiation therapy, immunotherapy, chemotherapy, vaccine therapy, and antiangiogenic therapies in the adjuvant setting. To date, none of these trials have demonstrated a significant benefit. Thus, the standard of care remains surveillance following surgical resection of locally advanced disease. Currently, clinical trials with the new targeted therapies developed for RCC are ongoing in the adjuvant setting. We anxiously await the results of these trials to determine whether they can significantly impact recurrence free and overall survival in the locally advanced setting following curative surgical resection.", 
    "editor": [
      {
        "familyName": "Bukowski", 
        "givenName": "Ronald M.", 
        "type": "Person"
      }, 
      {
        "familyName": "Figlin", 
        "givenName": "Robert A.", 
        "type": "Person"
      }, 
      {
        "familyName": "Motzer", 
        "givenName": "Robert J.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-59745-332-5_25", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-58829-737-2", 
        "978-1-59745-332-5"
      ], 
      "name": "Renal Cell Carcinoma", 
      "type": "Book"
    }, 
    "keywords": [
      "renal cell carcinoma", 
      "adjuvant setting", 
      "advanced disease", 
      "adjuvant therapy", 
      "metastatic disease", 
      "surgical resection", 
      "curative therapy", 
      "cell carcinoma", 
      "clinical trials", 
      "metastatic renal cell carcinoma", 
      "significant global health problem", 
      "adjuvant therapy setting", 
      "curative surgical resection", 
      "high-risk features", 
      "effective adjuvant therapy", 
      "risk of relapse", 
      "numerous clinical trials", 
      "standard of care", 
      "global health problem", 
      "overall survival", 
      "vaccine therapy", 
      "antiangiogenic therapy", 
      "radiation therapy", 
      "therapeutic benefit", 
      "advanced setting", 
      "health problems", 
      "therapy", 
      "natural history", 
      "patients", 
      "early detection", 
      "disease", 
      "trials", 
      "therapy setting", 
      "resection", 
      "relapse", 
      "surgery", 
      "carcinoma", 
      "significant benefits", 
      "risk", 
      "significant number", 
      "setting", 
      "immunotherapy", 
      "chemotherapy", 
      "recurrence", 
      "illness", 
      "mainstay", 
      "diagnosis", 
      "care", 
      "survival", 
      "surveillance", 
      "benefits", 
      "history", 
      "role", 
      "date", 
      "presence", 
      "search", 
      "detection", 
      "number", 
      "success", 
      "standards", 
      "features", 
      "results", 
      "inroads", 
      "approach", 
      "problem"
    ], 
    "name": "Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches", 
    "pagination": "473-495", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049745809"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-59745-332-5_25"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-59745-332-5_25", 
      "https://app.dimensions.ai/details/publication/pub.1049745809"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_451.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-59745-332-5_25"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-332-5_25'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-332-5_25'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-332-5_25'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-332-5_25'


 

This table displays all metadata directly associated to this object as RDF triples.

147 TRIPLES      22 PREDICATES      91 URIs      83 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-59745-332-5_25 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1112
4 schema:author N23e2d208c0c0490fa5adcc694887cc8c
5 schema:datePublished 2009
6 schema:datePublishedReg 2009-01-01
7 schema:description Renal cell carcinoma (RCC) remains a significant global health problem. Despite inroads in early detection, ̃50 %of patients either present with or develop metastatic disease during the natural history of their illness. There remains no consistent curative therapy for metastatic RCC. For patients with locally advanced disease, surgery remains the mainstay of curative therapy, but a significant number of patients still experience relapse, the risk of which is directly related to the presence of high-risk features at diagnosis. The search for effective adjuvant therapy to decrease the risk of relapse following surgery remains elusive. Therapeutic benefit in the setting of metastatic disease has not translated to success in the adjuvant therapy setting. Numerous clinical trials have examined the role of radiation therapy, immunotherapy, chemotherapy, vaccine therapy, and antiangiogenic therapies in the adjuvant setting. To date, none of these trials have demonstrated a significant benefit. Thus, the standard of care remains surveillance following surgical resection of locally advanced disease. Currently, clinical trials with the new targeted therapies developed for RCC are ongoing in the adjuvant setting. We anxiously await the results of these trials to determine whether they can significantly impact recurrence free and overall survival in the locally advanced setting following curative surgical resection.
8 schema:editor N96d670e390ce4814b767c869aa9b96b0
9 schema:genre chapter
10 schema:isAccessibleForFree false
11 schema:isPartOf N736b1340aa484b45ba6b54414efd01d1
12 schema:keywords adjuvant setting
13 adjuvant therapy
14 adjuvant therapy setting
15 advanced disease
16 advanced setting
17 antiangiogenic therapy
18 approach
19 benefits
20 carcinoma
21 care
22 cell carcinoma
23 chemotherapy
24 clinical trials
25 curative surgical resection
26 curative therapy
27 date
28 detection
29 diagnosis
30 disease
31 early detection
32 effective adjuvant therapy
33 features
34 global health problem
35 health problems
36 high-risk features
37 history
38 illness
39 immunotherapy
40 inroads
41 mainstay
42 metastatic disease
43 metastatic renal cell carcinoma
44 natural history
45 number
46 numerous clinical trials
47 overall survival
48 patients
49 presence
50 problem
51 radiation therapy
52 recurrence
53 relapse
54 renal cell carcinoma
55 resection
56 results
57 risk
58 risk of relapse
59 role
60 search
61 setting
62 significant benefits
63 significant global health problem
64 significant number
65 standard of care
66 standards
67 success
68 surgery
69 surgical resection
70 surveillance
71 survival
72 therapeutic benefit
73 therapy
74 therapy setting
75 trials
76 vaccine therapy
77 schema:name Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches
78 schema:pagination 473-495
79 schema:productId Ne4c32b897bec4ff883545d93345f78de
80 Nf743d5032f5b4d838531f5a9493614e5
81 schema:publisher Nb93e91cfc4f34de283946da809ae7ad8
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049745809
83 https://doi.org/10.1007/978-1-59745-332-5_25
84 schema:sdDatePublished 2022-10-01T06:59
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Nfb4a406627a249e4b2299f44d61bdf09
87 schema:url https://doi.org/10.1007/978-1-59745-332-5_25
88 sgo:license sg:explorer/license/
89 sgo:sdDataset chapters
90 rdf:type schema:Chapter
91 N1b980f0b7c0747228b85809835b93a82 schema:affiliation grid-institutes:grid.241167.7
92 schema:familyName Kadar
93 schema:givenName A. Karim
94 rdf:type schema:Person
95 N23e2d208c0c0490fa5adcc694887cc8c rdf:first N1b980f0b7c0747228b85809835b93a82
96 rdf:rest Ne0f9fff21d05491089213c854c60d895
97 N718c2ede8ed7427e9b6747f61ff021bf schema:familyName Bukowski
98 schema:givenName Ronald M.
99 rdf:type schema:Person
100 N736b1340aa484b45ba6b54414efd01d1 schema:isbn 978-1-58829-737-2
101 978-1-59745-332-5
102 schema:name Renal Cell Carcinoma
103 rdf:type schema:Book
104 N80cb929e3423438eafb43e3a364e72a0 schema:familyName Motzer
105 schema:givenName Robert J.
106 rdf:type schema:Person
107 N8f6c0c2376c040938f8b213ca3fcc107 rdf:first N80cb929e3423438eafb43e3a364e72a0
108 rdf:rest rdf:nil
109 N96d670e390ce4814b767c869aa9b96b0 rdf:first N718c2ede8ed7427e9b6747f61ff021bf
110 rdf:rest Nc5018326df9749888356945060ec439a
111 Nb93e91cfc4f34de283946da809ae7ad8 schema:name Springer Nature
112 rdf:type schema:Organisation
113 Nbbdd9db0d2304c6ebf659420d9ee1b5d schema:familyName Figlin
114 schema:givenName Robert A.
115 rdf:type schema:Person
116 Nc5018326df9749888356945060ec439a rdf:first Nbbdd9db0d2304c6ebf659420d9ee1b5d
117 rdf:rest N8f6c0c2376c040938f8b213ca3fcc107
118 Ne0f9fff21d05491089213c854c60d895 rdf:first sg:person.01040121722.56
119 rdf:rest rdf:nil
120 Ne4c32b897bec4ff883545d93345f78de schema:name dimensions_id
121 schema:value pub.1049745809
122 rdf:type schema:PropertyValue
123 Nf743d5032f5b4d838531f5a9493614e5 schema:name doi
124 schema:value 10.1007/978-1-59745-332-5_25
125 rdf:type schema:PropertyValue
126 Nfb4a406627a249e4b2299f44d61bdf09 schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
129 schema:name Medical and Health Sciences
130 rdf:type schema:DefinedTerm
131 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
132 schema:name Clinical Sciences
133 rdf:type schema:DefinedTerm
134 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
135 schema:name Oncology and Carcinogenesis
136 rdf:type schema:DefinedTerm
137 sg:person.01040121722.56 schema:affiliation grid-institutes:None
138 schema:familyName Wood
139 schema:givenName Christopher G.
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
141 rdf:type schema:Person
142 grid-institutes:None schema:alternateName Department of Urology, MD Anderson Cancer Center, University of Texas, 77030, TX, Houston
143 schema:name Department of Urology, MD Anderson Cancer Center, University of Texas, 77030, TX, Houston
144 rdf:type schema:Organization
145 grid-institutes:grid.241167.7 schema:alternateName Wake Forest University School of Medicine, Winston-Salem, NC
146 schema:name Wake Forest University School of Medicine, Winston-Salem, NC
147 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...